NEW HAVEN, Conn., May 1, 2026
Arvinas, Inc., in collaboration with Pfizer Inc., announced that the U.S. Food and Drug Administration (FDA) has approved VEPPANU™ (vepdegestrant) for the treatment of estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer in adults who have progressed after at least one line of endocrine therapy. This approval marks a historic milestone as the first-ever FDA-approved PROTAC (PROteolysis Targeting Chimera) therapy, introducing a new class of targeted protein degradation medicines into clinical oncology.
First-in-Class PROTAC Therapy Targets Resistance Mechanism
VEPPANU represents a breakthrough innovation in cancer treatment, leveraging PROTAC technology to selectively degrade disease-causing proteins rather than simply inhibiting them. Specifically designed to target the estrogen receptor (ER), the therapy addresses a major challenge in advanced breast cancer—treatment resistance driven by ESR1 mutations, which occur in up to 40–50% of patients following endocrine therapy and CDK4/6 inhibitor treatment.
By degrading the mutated estrogen receptor, VEPPANU offers a novel mechanism to overcome resistance and restore therapeutic response, positioning it as a critical addition to the treatment landscape for patients with limited second-line options.
Phase 3 Data Shows Significant Progression-Free Survival Benefit
Advertisement
The FDA approval is supported by results from the global Phase 3 VERITAC-2 trial, which demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to fulvestrant, the current standard of care. Among patients with ESR1 mutations (n=270), VEPPANU reduced the risk of disease progression or death by 43% (hazard ratio: 0.57; p=0.0001).
Median PFS was 5 months for VEPPANU versus 2.1 months for fulvestrant, highlighting a substantial benefit in delaying disease progression. The treatment was generally well tolerated, with most adverse events classified as low grade (Grade 1–2). Common side effects included decreased blood cell counts, liver enzyme elevations, fatigue, nausea, and musculoskeletal pain, consistent with expectations for targeted oncology therapies.
Strategic Commercialization and Pipeline Expansion
The approval of VEPPANU marks Arvinas’ first commercial product and validates over a decade of innovation in targeted protein degradation technology. The company, together with Pfizer, plans to appoint a third-party commercialization partner to maximize global market reach and ensure rapid patient access.
This milestone also strengthens confidence in Arvinas’ broader pipeline, which includes multiple PROTAC-based therapies targeting oncology and neurodegenerative diseases. With this approval granted ahead of the FDA’s assigned PDUFA date, the companies have demonstrated strong regulatory alignment and execution efficiency. Importantly, VEPPANU introduces a convenient oral alternative to injectable therapies like fulvestrant, improving patient experience while delivering superior clinical outcomes.
The approval underscores a paradigm shift in drug development, where targeted protein degradation is emerging as a powerful strategy to address previously undruggable targets and resistance mechanisms. As the first approved therapy of its kind, VEPPANU is expected to pave the way for a new generation of precision medicines, potentially transforming treatment approaches across multiple disease areas.
Source: Arvinas press release
